Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6345310 | 0.80 | CHRNA7 (0.51) | CHRNA7CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL6354836 | 0.77 | CHRNA7 (0.55) | CHRNA7CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL6343635 | 0.76 | CHRM2 (0.50) | CHRNA7CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL6344390 | 0.75 | CHRNA7 (0.49) | CHRNA7CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL9431132 | 0.74 | CHRNA7 (0.56) | CHRNA7CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL4199213 | 0.72 | CHRM2 (0.52) | CHRNA7CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL6346098 | 0.72 | MEN1 (0.49) | CHRNA7CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL9458933 | 0.71 | CHRNA7 (0.43) | CHRNA7 | |
| SCHEMBL20342557 | 0.71 | HDAC4 (0.48) | — | |
| Methane SCHEMBL4192825 | 0.71 | CHRM2 (0.50) | CHRNA7CHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044026-A1 | 3-Substituted quinuclidines and their use as nicotinic agonists | ANIONA APS (DK) | 2004-03-04 | — | — | US | claimed |
| EP-1339712-A1 | 3-SUBSTITUTED QUINUCLIDINES AND THEIR USE AS NICOTINIC AGONISTS | NEUROSEARCH A/S (DK) | 2003-09-03 | — | — | EP | claimed |
| WO-2002044176-A1 | 3-SUBSTITUTED QUINUCLIDINES AND THEIR USE AS NICOTINIC AGONISTS | NEUROSEARCH A/S (DK) | 2002-06-06 | — | — | WO | claimed |
| US-6884807-B2 | 3-substituted quinuclidines and their use as nicotinic agonists | NEUROSEARCH, A/S (DE) | 2005-04-26 | — | — | US | disclosed |
| US-20040044026-A1 | 3-Substituted quinuclidines and their use as nicotinic agonists | ANIONA APS (DK) | 2004-03-04 | — | — | US | disclosed |
| EP-1339712-A1 | 3-SUBSTITUTED QUINUCLIDINES AND THEIR USE AS NICOTINIC AGONISTS | NEUROSEARCH A/S (DK) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002044176-A1 | 3-SUBSTITUTED QUINUCLIDINES AND THEIR USE AS NICOTINIC AGONISTS | NEUROSEARCH A/S (DK) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044026-A1 | 3-Substituted quinuclidines and their use as nicotinic agonists | CHRNA3, CHRNA5, CHRNA7 | CHRNA7 3/4885CHRM2 23/4885CHRM4 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.